文献速递瓣膜外科

生物瓣与机械瓣置换治疗感染性心内膜炎:聚焦复发率

Bioprosthetic Versus Mechanical Valve Replacement for Infective Endocarditis: Focus on Recurrence Rates.
PubMed 文献 · Ann Thorac Surg · 2018-02-13

基于加州和纽约强制出院数据库1998至2010年间3447例活动性心内膜炎行孤立二尖瓣(1603例)或主动脉瓣(1844例)置换的患者,比较生物瓣(1673例,48.5%)与机械瓣(1774例,51.5%)的结局。中位随访6.8年,两组12年生存率和心内膜炎复发率均无显著差异。

要点

  • 生物瓣组患者更年长(60.4±14.9岁 vs 53.4±14.3岁,p<0.001)且合并症更多。
  • 二尖瓣置换后12年生存率生物瓣 vs 机械瓣调整HR 1.14(95%CI 0.98-1.34,p=0.10),无显著差异。
  • 主动脉瓣置换后12年复发率生物瓣9.4% vs 机械瓣10.0%,调整Cox p=0.81,无显著差异。

核心结论

  • 生物瓣与机械瓣在生存率和免于心内膜炎复发方面表现相似,数据支持指南推荐由患者因素决定瓣膜选择。

研究设计与样本

  • 回顾性队列研究,数据来自加州和纽约强制出院数据库,纳入1998至2010年间因活动性心内膜炎行初次孤立二尖瓣(n=1603)或主动脉瓣(n=1844)置换的3447例患者,比较生物瓣(n=1673,48.5%)与机械瓣(n=1774,51.5%),药物滥用者作为单独队列分析,主要结局为心内膜炎复发,中位随访6.8年(范围0至12),生存随访截至2015年12月31日。

主要发现

  • 生物瓣组患者年龄更大(60.4±14.9岁 vs 53.4±14.3岁,p<0.001)且合并症更多。
  • 二尖瓣置换后12年生存率生物瓣 vs 机械瓣调整HR 1.14(95%CI 0.98-1.34,p=0.10),无显著差异。
  • 主动脉瓣置换后12年生存率生物瓣 vs 机械瓣调整HR 1.10(95%CI 0.93-1.29,p=0.26),无显著差异。
  • 二尖瓣置换后12年复发率生物瓣10.4%(95%CI 8.0%-13.1%) vs 机械瓣8.8%(95%CI 6.9%-10.9%),调整Cox p=0.79,无显著差异。
  • 主动脉瓣置换后12年复发率生物瓣9.4%(95%CI 7.5%-11.6%) vs 机械瓣10.0%(95%CI 8.0%-12.4%),调整Cox p=0.81,无显著差异。

临床怎么用

  • 原文结论认为数据支持指南推荐由患者因素决定感染性心内膜炎的瓣膜选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Consensus guidelines for prosthesis selection in infective endocarditis recommend bioprosthetic or mechanical valve replacement based on life expectancy and comorbidity. However, contemporary outcome data are limited to institution series. METHODS: The outcomes of 3,447 patients identified from mandatory discharge databases in California and New York who had either primary isolated mitral (n = 1,603) or aortic (n = 1,844) valve replacement for active endocarditis between 1998 and 2010 were compared according to whether they received bioprosthetic (n = 1,673, 48.5%) or mechanical (n = 1,774, 51.5%) valves. Drug abusers were analyzed as a separate cohort. The primary outcome was endocarditis recurrence. Median follow-up time was 6.8 years (range, 0 to 12). Last follow-up for survival was December 31, 2015. RESULTS: Patients receiving bioprosthetic valves were older (60.4 ± 14.9 versus 53.4 ± 14.3 years, p < 0.001), with more comorbidity. There was no significant difference in 12-year survival with bioprosthetic versus mechanical valves after mitral (adjusted hazard ratio 1.14, 95% confidence interval [CI]: 0.98 to 1.34, p = 0.10) or aortic (adjusted hazard ratio 1.10, 95% CI: 0.93 to 1.29, p = 0.26) valve replacement. Bioprosthetic and mechanical valves were associated with similar recurrence rates at 12 years: 10.4% (95% CI: 8.0% to 13.1%) versus 8.8% (95% CI: 6.9% to 10.9%), adjusted Cox p = 0.79 after mitral replacement; and 9.4% (95% CI: 7.5% to 11.6%) versus 10.0% (95% CI: 8.0% to 12.4%), adjusted Cox p = 0.81 after aortic valve replacement. CONCLUSIONS: Bioprosthetic and mechanical valves are associated with similar survival and freedom from endocarditis recurrence. These data support guideline recommendations that patient factors guide prosthesis choice in infective endocarditis.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Toyoda N, Itagaki S, Tannous H, et al. Bioprosthetic Versus Mechanical Valve Replacement for Infective Endocarditis: Focus on Recurrence Rates. Ann Thorac Surg. 2018. PMID: 29452115. doi:10.1016/j.athoracsur.2017.12.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。